{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:10:05Z","timestamp":1750335005019,"version":"3.41.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jocn.2025.111338","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:55:31Z","timestamp":1747655731000},"page":"111338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-Amyloid Agents: A Self-Fulfilling prophecy"],"prefix":"10.1016","volume":"137","author":[{"given":"Alexandros","family":"Giannakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spiridon","family":"Konitsiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2025.111338_b0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10654-021-00745-5","article-title":"Dementia remains the major predictor of death among octogenarians. A study of two population cohorts of 85-year-olds examined 22years apart","volume":"36","author":"Wetterberg","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jocn.2025.111338_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2023.09.008","article-title":"Economic Burden of Alzheimer\u2019s Disease: A Systematic Review","volume":"40","author":"Tay","year":"2024","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jocn.2025.111338_b0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging\u2010Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.jocn.2025.111338_b0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA\u2010AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.jocn.2025.111338_b0025","doi-asserted-by":"crossref","DOI":"10.1177\/13872877251325891","article-title":"The unsafe profile of lecanemab","author":"H\u00f8ilund-Carlsen","year":"2025","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.jocn.2025.111338_b0030","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.jocn.2025.111338_b0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2025.111338_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2023.100467","article-title":"Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer\u2019s disease: patient outcomes, healthcare costs, and drug development","volume":"20","author":"Brockmann","year":"2023","journal-title":"The Lancet Regional Health - Americas"},{"key":"10.1016\/j.jocn.2025.111338_b0045","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s10072-023-07194-w","article-title":"Efficacy of anti-amyloid-\u00df monoclonal antibody therapy in early Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"45","author":"Dantas","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jocn.2025.111338_b0050","first-page":"524","article-title":"FDA Green-Lights Second Alzheimer Drug","volume":"332","author":"Harris","year":"2024","journal-title":"Donanemab JAMA"},{"key":"10.1016\/j.jocn.2025.111338_b0055","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3233\/JAD-220262","article-title":"Making the Case for Accelerated Withdrawal of Aducanumab","volume":"87","author":"Whitehouse","year":"2022","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.jocn.2025.111338_b0060","doi-asserted-by":"crossref","first-page":"25741","DOI":"10.1038\/s41598-024-75204-8","article-title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer\u2019s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","volume":"14","author":"Avgerinos","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jocn.2025.111338_b0065","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00259-023-06177-5","article-title":"FDA approval of lecanemab: the real start of widespread amyloid PET use? \u2014 the EANM Neuroimaging Committee perspective","volume":"50","author":"Verger","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jocn.2025.111338_b0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/biom13020313","article-title":"The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells","volume":"13","author":"Cai","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jocn.2025.111338_b0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.jocn.2025.111338_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2024.12.002","article-title":"Anti-Amyloid Therapies for Alzheimer\u2019s Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician","author":"Rech","year":"2025","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jocn.2025.111338_b0085","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp-2024-333468","article-title":"Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer\u2019s disease","volume":"95","author":"Dobson","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2025.111338_b0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jnnp-2024-333941","article-title":"Predicting how many people might receive treatment with new therapies for Alzheimer\u2019s disease","volume":"95","author":"Underwood","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"261","key":"10.1016\/j.jocn.2025.111338_b0095","first-page":"921","article-title":"Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer\u2019s Disease in Late Onset Families","volume":"1993","author":"Corder","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jocn.2025.111338_b0100","doi-asserted-by":"crossref","unstructured":"Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele \u220a4 with late\u2010onset familial and sporadic Alzheimer\u2019s disease. Neurology 1993;43:1467\u20131467. https:\/\/doi.org\/10.1212\/WNL.43.8.1467.","DOI":"10.1212\/WNL.43.8.1467"},{"key":"10.1016\/j.jocn.2025.111338_b0105","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","article-title":"Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jocn.2025.111338_b0110","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"ApoE and A\u03b2 in Alzheimer\u2019s Disease: Accidental Encounters or Partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.jocn.2025.111338_b0115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tem.2023.05.002","article-title":"Apolipoprotein E in lipid metabolism and neurodegenerative disease","volume":"34","author":"Yang","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jocn.2025.111338_b0120","first-page":"68","article-title":"APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches","volume":"20","author":"Serrano-Pozo","year":"2021","journal-title":"LancetNeurol"},{"key":"10.1016\/j.jocn.2025.111338_b0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-170970","article-title":"Linking Atrial Fibrillation with Alzheimer\u2019s Disease: Epidemiological, Pathological, and Mechanistic Evidence","volume":"62","author":"Ihara","year":"2018","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.jocn.2025.111338_b0130","article-title":"Cognitive Impairment and Dementia in AtrialFibrillation. JACC","volume":"2","author":"Chung","year":"2023","journal-title":"Advances"},{"key":"10.1016\/j.jocn.2025.111338_b0135","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/jcm13051245","article-title":"The Impact of Anti-Amyloid Immunotherapies on Stroke Care","volume":"13","author":"Bilodeau","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jocn.2025.111338_b0140","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2025.111338_b0145","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1192\/bjo.2024.747","article-title":"Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer\u2019s disease: real-world data from an Austrian psychiatric memory clinic population","volume":"10","author":"Defrancesco","year":"2024","journal-title":"BJPsych Open"},{"key":"10.1016\/j.jocn.2025.111338_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100102","article-title":"Patient eligibility for amyloid-targeting immunotherapies in Alzheimer\u2019s disease","volume":"12","author":"Rosen","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.jocn.2025.111338_b0155","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2025.111338_b0160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2025.111338_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2022.100256","article-title":"Preventable risk factors of dementia: Population attributable fractions in a Brazilian population-based study","volume":"11","author":"Borelli","year":"2022","journal-title":"The Lancet Regional Health - Americas"},{"key":"10.1016\/j.jocn.2025.111338_b0170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JAD-180802","article-title":"Understanding the Amyloid Hypothesis in Alzheimer\u2019s Disease","volume":"68","author":"Paroni","year":"2019","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.jocn.2025.111338_b0175","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1212\/WNL.0b013e318295d7a1","article-title":"Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology","volume":"80","author":"Monsell","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2025.111338_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.617588","article-title":"Mitochondrial Dysfunction and Oxidative Stress in Alzheimer\u2019s Disease","volume":"13","author":"Misrani","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.jocn.2025.111338_b0185","article-title":"Neuroinflammation in Alzheimer disease","author":"Heneka","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jocn.2025.111338_b0190","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/193229680800200619","article-title":"Alzheimer\u2019s Disease is Type 3 Diabetes\u2014Evidence Reviewed","volume":"2","author":"de la Monte","year":"2008","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jocn.2025.111338_b0195","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.3390\/ijms252211955","article-title":"Alzheimer\u2019s Disease as Type 3 Diabetes: Understanding the Link and Implications","volume":"25","author":"Kciuk","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jocn.2025.111338_b0200","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/biom11070960","article-title":"Copper Imbalance in Alzheimer\u2019s Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating ATP7B Gene Variants","volume":"11","author":"Squitti","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jocn.2025.111338_b0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3233\/JAD-201556","article-title":"Copper Imbalance in Alzheimer\u2019s Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology","volume":"83","author":"Squitti","year":"2021","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.jocn.2025.111338_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117814","article-title":"Cuproptosis and copper as potential mechanisms and intervention targets in Alzheimer\u2019s disease","volume":"183","author":"Li","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jocn.2025.111338_b0215","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/s41380-022-01802-5","article-title":"Brain copper may protect from cognitive decline and Alzheimer\u2019s disease pathology: a community-based study","volume":"27","author":"Agarwal","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jocn.2025.111338_b0220","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer\u2019s Disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2025.111338_b0225","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of Solanezumab in Preclinical Alzheimer\u2019s Disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2025.111338_b0230","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","article-title":"Disease staging of Alzheimer\u2019s disease using a CSF-based biomarker model","volume":"4","author":"Salvad\u00f3","year":"2024","journal-title":"Nat Aging"},{"key":"10.1016\/j.jocn.2025.111338_b0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/diagnostics9020065","article-title":"The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer\u2019s Disease\u2014Review of Literature and Interesting Images","volume":"9","author":"Suppiah","year":"2019","journal-title":"Diagnostics"},{"key":"10.1016\/j.jocn.2025.111338_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2019.101002","article-title":"A third of community-dwelling elderly with intermediate and high level of Alzheimer\u2019s neuropathologic changes are not demented: A meta-analysis","volume":"58","author":"Azarpazhooh","year":"2020","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.jocn.2025.111338_b0245","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1212\/WNL.38.11.1682","article-title":"Clinico\u2010pathologic studies in dementia","volume":"38","author":"Crystal","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2025.111338_b0250","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/NEN.0b013e31822e8ae9","article-title":"Alzheimer Disease Pathology in Subjects Without Dementia in 2 Studies of Aging: The Nun Study and the Adult Changes in Thought Study","volume":"70","author":"SantaCruz","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jocn.2025.111338_b0255","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.4103\/1673-5374.385847","article-title":"Targeting tau in Alzheimer\u2019s disease: from mechanisms to clinical therapy","volume":"19","author":"Ye","year":"2024","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.jocn.2025.111338_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.07.001","article-title":"Public beliefs and knowledge about risk and protective factors for Alzheimer\u2019s disease","volume":"10","author":"Roberts","year":"2014","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.jocn.2025.111338_b0265","first-page":"16","article-title":"Attitudes to dementia, a global survey","volume":"2020","author":"Lynch C. World Alzheimer Report","year":"2019","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.jocn.2025.111338_b0270","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awy153","article-title":"A broader view of dementia: multiple co-pathologies are the norm","volume":"141","author":"Coulthard","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2025.111338_b0275","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2025.111338_b0280","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","article-title":"Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank","volume":"16","author":"Barker","year":"2002","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.jocn.2025.111338_b0285","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mds.27867","article-title":"Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases","volume":"35","author":"Coughlin","year":"2020","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2025.111338_b0290","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/alz.13422","article-title":"Different cohort, disparate results: Selection bias is a key factor in autopsy cohorts","volume":"20","author":"Gauthreaux","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.jocn.2025.111338_b0295","doi-asserted-by":"crossref","first-page":"12214","DOI":"10.1038\/s41598-022-16476-w","article-title":"Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia","volume":"12","author":"Zuin","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jocn.2025.111338_b0300","doi-asserted-by":"crossref","unstructured":"Khasawneh RR, Abu-El-Rub E, Alzu\u2019bi A, Abdelhady GT, Al-Soudi HS. Corpus callosum anatomical changes in Alzheimer patients and the effect of acetylcholinesterase inhibitors on corpus callosum morphometry. PLoS One 2022;17:e0269082. https:\/\/doi.org\/10.1371\/journal.pone.0269082.","DOI":"10.1371\/journal.pone.0269082"},{"key":"10.1016\/j.jocn.2025.111338_b0305","series-title":"Callosum in Dementia. The Corpus Callosum","first-page":"269","author":"Corpus","year":"2023"},{"key":"10.1016\/j.jocn.2025.111338_b0310","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41401-018-0206-4","article-title":"Donepezil, a drug for Alzheimer\u2019s disease, promotes oligodendrocyte generation and remyelination","volume":"40","author":"Cui","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jocn.2025.111338_b0315","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14283\/jpad.2018.43","article-title":"Revisiting the Cholinergic Hypothesis in Alzheimer\u2019s Disease: Emerging Evidence from Translational and Clinical Research","volume":"6","author":"Hampel","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.jocn.2025.111338_b0320","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/ATVBAHA.120.311911","article-title":"Vascular Hypothesis of Alzheimer Disease","volume":"41","author":"Scheffer","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jocn.2025.111338_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010929","article-title":"Infectious origin of Alzheimer\u2019s disease: Amyloid beta as a component of brain antimicrobial immunity","volume":"18","author":"Vojtechova","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jocn.2025.111338_b0330","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1281338","article-title":"Proteostasis and neurodegeneration: a closer look at autophagy in Alzheimer\u2019s disease","volume":"15","author":"Barmaki","year":"2023","journal-title":"Front Aging Neurosci"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825003108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825003108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:30:12Z","timestamp":1750332612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825003108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":66,"alternative-id":["S0967586825003108"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111338","relation":{},"ISSN":["0967-5868"],"issn-type":[{"type":"print","value":"0967-5868"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Amyloid Agents: A Self-Fulfilling prophecy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111338"}}